204 related articles for article (PubMed ID: 31295448)
1. Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone.
Adeyanju OA; Falodun TO; Fabunmi OA; Olatunji LA; Soladoye AO
Chem Biol Interact; 2019 Sep; 310():108742. PubMed ID: 31295448
[TBL] [Abstract][Full Text] [Related]
2. Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS.
Olaniyi KS; Oniyide AA; Adeyanju OA; Ojulari LS; Omoaghe AO; Olaiya OE
Toxicol Appl Pharmacol; 2021 Jan; 411():115381. PubMed ID: 33359182
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid-a familiar foe.
Adeyanju OA; Falodun TO; Michael OS; Soetan OA; Oyewole AL; Agbana RD
Naunyn Schmiedebergs Arch Pharmacol; 2020 Jun; 393(6):1055-1066. PubMed ID: 31925474
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid receptor blockade attenuates hyperandrogenic metabolic dysregulation in letrozole-induced PCOS rat model.
Uhunmwangho EG; Oniyide AA; Areloegbe SE; Soetan OA; Akintayo CO; Aturamu A; Olaniyi KS
J Diabetes Metab Disord; 2022 Dec; 21(2):1539-1547. PubMed ID: 36404823
[TBL] [Abstract][Full Text] [Related]
5. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
[TBL] [Abstract][Full Text] [Related]
6. Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS.
Ryan GE; Malik S; Mellon PL
Endocrinology; 2018 Apr; 159(4):1734-1747. PubMed ID: 29471436
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of GABA against metabolic and reproductive disturbances in letrozole induced polycystic ovarian syndrome in rats.
Ullah A; Jahan S; Razak S; Pirzada M; Ullah H; Almajwal A; Rauf N; Afsar T
J Ovarian Res; 2017 Sep; 10(1):62. PubMed ID: 28915843
[TBL] [Abstract][Full Text] [Related]
8. Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model.
Peter MU; Areloegbe SE; Akintayo CO; Oniyide AA; Aturamu A; Olaniyi KS
Can J Physiol Pharmacol; 2022 Sep; 100(9):890-902. PubMed ID: 35771488
[TBL] [Abstract][Full Text] [Related]
9. Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model.
Areloegbe SE; Peter MU; Oyeleke MB; Olaniyi KS
BMC Endocr Disord; 2022 Sep; 22(1):224. PubMed ID: 36071485
[TBL] [Abstract][Full Text] [Related]
10. Agaricus Subrufescens ameliorates ovarian dysfunction and regulates altered biochemical parameters in rats with Letrozole induced polycystic ovarian syndrome.
Bukke SPN; Pathange BBR; Karumanchi SK; Marri J; Boyina R; Rachamsetty K; Manchikalapati B; Odoma S; Hussaini B
J Ovarian Res; 2023 Nov; 16(1):221. PubMed ID: 37993900
[TBL] [Abstract][Full Text] [Related]
11. Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome.
Olaniyi KS; Areloegbe SE; Areola ED; Sabinari IW; Fafure AA; Agbana RD; Atuma CL; Shah MZUH; Ajadi IO; Olatunji LA
Toxicol Appl Pharmacol; 2023 Aug; 473():116604. PubMed ID: 37328115
[TBL] [Abstract][Full Text] [Related]
12. Ficus deltoidea ameliorates biochemical, hormonal, and histomorphometric changes in letrozole-induced polycystic ovarian syndrome rats.
Haslan MA; Samsulrizal N; Hashim N; Zin NSNM; Shirazi FH; Goh YM
BMC Complement Med Ther; 2021 Nov; 21(1):291. PubMed ID: 34844580
[TBL] [Abstract][Full Text] [Related]
13. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
[TBL] [Abstract][Full Text] [Related]
14. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome.
Vieira CS; Martins WP; Fernandes JB; Soares GM; dos Reis RM; de Sá MF; Ferriani RA
Contraception; 2012 Sep; 86(3):268-75. PubMed ID: 22464410
[TBL] [Abstract][Full Text] [Related]
15. A Rat Model of Polycystic Ovary Syndrome with Insulin Resistance Induced by Letrozole Combined with High Fat Diet.
Wang MX; Yin Q; Xu X
Med Sci Monit; 2020 May; 26():e922136. PubMed ID: 32448863
[TBL] [Abstract][Full Text] [Related]
16. Soy isoflavones exert beneficial effects on letrozole-induced rat polycystic ovary syndrome (PCOS) model through anti-androgenic mechanism.
Rajan RK; M SS; Balaji B
Pharm Biol; 2017 Dec; 55(1):242-251. PubMed ID: 27927075
[TBL] [Abstract][Full Text] [Related]
17. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome.
Gökmen O; Senöz S; Gülekli B; Işik AZ
Gynecol Endocrinol; 1996 Aug; 10(4):249-55. PubMed ID: 8908525
[TBL] [Abstract][Full Text] [Related]
18. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome.
Studen KB; Sebestjen M; Pfeifer M; Prezelj J
Eur J Endocrinol; 2011 Mar; 164(3):389-95. PubMed ID: 21156647
[TBL] [Abstract][Full Text] [Related]
19. Spironolactone as a single agent for long-term therapy of hirsute patients.
Spritzer PM; Lisboa KO; Mattiello S; Lhullier F
Clin Endocrinol (Oxf); 2000 May; 52(5):587-94. PubMed ID: 10792338
[TBL] [Abstract][Full Text] [Related]
20. Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
Kulshreshtha B; Gupta N; Ganie MA; Ammini AC
Gynecol Endocrinol; 2012 Oct; 28(10):823-6. PubMed ID: 22475072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
